Fosun Pharma sees profit surge on asset sales, share buybacks

Fosun Pharma reported a profit attributable to owners of the parent of RMB1,702 million for the first half of 2025, a 38.94% increase compared to the previous year. This was primarily driven by the disposal of remaining equity interest in United Family Healthcare and other non-core assets. Revenue for the period reached RMB19,426 million, a 4.70% decrease year-on-year, though innovative drugs saw robust growth exceeding RMB4,300 million, up 14.26%. Net cash flow from operating activities increased by 11.90% to RMB2,134 million, supported by supply chain optimization. The debt-to-asset ratio slightly increased to 49.26% from 48.99% at the end of 2024.

During the reporting period, Fosun Pharma also engaged in significant share repurchase programs. The company repurchased 3,410,500 H Shares totaling approximately HK$47.84 million and 14,228,552 A Shares amounting to approximately RMB348.36 million. Additionally, the company completed the issuance of the first tranche of medium-term notes for RMB500 million with a 3.10% coupon rate and two-year terms. Total R&D expenditure amounted to RMB2,584 million, with RMB1,717 million expensed, demonstrating continued investment in innovation.